MedPath

Memantine versus Valproate in episodic migraine

Not Applicable
Conditions
Migraine without aura.
Migraine without aura [common migraine]
Registration Number
IRCT2013112611424N2
Lead Sponsor
Vice Chancellor for research of Tehran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
60
Inclusion Criteria

Men and women diagnosed with migraine within an age range of 18-65 and the onset of disease before their 50s; The duration of migraine is at least 1 year; at least 6 attacks per month; at least 48 hours without headache between 2 attacks; no migraine prophylaxis until inclusion
Exclusion criteria:Renal dysfunction; Having ICDH-II criteria for medication overuse headache; Taking antipsychotics or antidepressants in last 3 months; Drug or alcohol abuse; Allergic reactions to memantine and Its compounds; Resistance to all acute migraine medications; Pain disorders; severe psychiatric disorder; Severe infections; Malignancy; Low chance of survival; Severe cardiac and vascular diseases; Neurodegenerative diseases; Pregnancy and lactation; Women in childbearing age and sexually active are included in the study, only if they receive contraception; MIDAS greater than 18

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The average number of attacks in each month. Timepoint: 3 months of retrospective history taking before intervention, 1 month of prospective history taking before intervention, 3 months after onset of intervention. Method of measurement: Migraine diary.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath